Organic compounds

US8759365B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Muneto Mogi · Waltham, US
• Toshio Kawanami · Belmont, US
• Ken Yamada · Brookline, US
• Kayo Yasoshima · Cambridge, US
• Hidetomo Imase · Somerville, US
• Takahiro Miyake · Kasai, JP
• Osamu Ohmori · Tsukuba, JP

Key dates

• Filing date: Dec 1, 2008
• Grant date: Jun 24, 2014
• Expiry date: Jul 29, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.